Clinical Trials | March 31, 2026
Bristol Myers Squibb’s Camzyos shows breakthrough results in adolescents with obstructive hypertrophic cardiomyopathy
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
